Survodutide
Also known as: BI 456906
Educational content only. This page does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making decisions related to any medication or health intervention.
Overview
Survodutide (BI 456906) is an investigational synthetic peptide developed by Boehringer Ingelheim that acts as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Like mazdutide, survodutide is designed to combine incretin-mediated appetite suppression with glucagon-driven increases in energy expenditure and lipid metabolism.
Survodutide is administered as a once-weekly subcutaneous injection. It is currently being evaluated in multiple Phase 3 clinical trial programs and has not been approved by any regulatory authority for any indication as of early 2026.
Research & Clinical Context
Phase 2 data, published and presented at major medical conferences, evaluated survodutide at multiple dose levels in adults with overweight or obesity across 12 countries over 46 weeks. Results showed dose-dependent weight reductions, with higher doses demonstrating substantial effects. Survodutide has also been studied in the context of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), where Phase 2 data showed improvements in liver histology.
Phase 3 programs include the SYNCHRONIZE series (evaluating survodutide for obesity with or without type 2 diabetes and cardiovascular disease) and the ACHIEVE series (evaluating survodutide for MASH). These trials are enrolling participants across multiple countries and are expected to report results through 2026. The SYNCHRONIZE-2 trial specifically studies survodutide in adults with obesity and type 2 diabetes, with primary endpoints including body weight change and weight loss thresholds.
References
- ClinicalTrials.gov: SYNCHRONIZE-2 (Survodutide Phase 3)
ClinicalTrials.gov
- Wharton S, et al. "Design of SYNCHRONIZE-2." Diabetes Obes Metab (2026)
Diabetes, Obesity and Metabolism
- Boehringer Ingelheim Survodutide Pipeline Page
Boehringer Ingelheim
Safety & Regulatory Notes
Survodutide is an investigational drug that has not been approved by the FDA or any other regulatory authority. It is available only through enrollment in clinical trials. The Phase 2 safety profile was generally consistent with other incretin-class therapies, with gastrointestinal side effects being the most common.
As an investigational compound, survodutide is not legally available outside of clinical trials. Regulations vary by country. Readers should consult a licensed healthcare provider for decisions regarding investigational therapies or clinical trial enrollment.
How This Fits Into Our Peptide Hub
Survodutide is tracked in our pipeline and next-generation metabolic peptide sections. It is commonly compared with mazdutide (the other leading dual GLP-1/glucagon agonist) and with retatrutide (the triple agonist) in our educational comparisons.